Embedded mobile icon means website can be accessed on the move in just one click
Almac has announced the launch of a mobile optimised version of its website, enabling biotech and pharma clients and prospective customers to access Almac’s content whilst out of the office with only a mobile to hand. The new mobile ready site (designed to work with all mobile operating systems including Android and Apple) contains shortened summaries of all the sections of Almac’s full website broken-down into 6 tabs – ‘Services’, ‘News’, ‘Events’, ‘Locations’, ‘Contact Us’, and ‘Vacancies’.
The new website was created in response to client demands; due to an ever growing number of visitors accessing the main site via mobile devices. The mobile ready site enables users to store an Almac icon on their phone’s screen providing rapid access in just one click, enhanced resolution for all screens sizes, and a search facility enabling visitors to access any content from the full site.
“At Almac we are always looking to help clients with any requirements they have and by launching this new mobile website we are providing even greater accessibility for the significant number of people that view our services and locations through mobile devices. We are one of the first CDMO companies to invest in online technologies to respond to this growing need, providing up to date information on our global portfolio helping to facilitate real time decision making wherever you are.” said Philip Diamond, VP Corporate Market ;Development at Almac.
The new site can be visited on the following address: http://m.almacgroup.com/
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.